Fisher Scientific International Inc
Fisher Scientific International — Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference 2006
12 slides from Fisher Scientific International's conference presentation, Feb 9, 2006
Slide 1: Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference February 9, 2006
Slide 2: Safe Harbor Statement and Regulation G Statement
The Securities and Exchange Commission encourages companies to disclose forward-looking information so that investors can better understand a company's future prospects and make informed investment decisions. This presentation contains these types of statements, which are "forward-looking statements
Slide 3: The World Leader in Serving Science
The World Leader in Serving Science Leading supplier to scientific markets One-stop shop for the scientist Reducing complexity in the lab
Slide 4: Track Record of Accomplishment
Sales Operating Margin* Stock Price Equity Market Cap. Track Record of Accomplishment 1991 2006F $0.8 5.2% $3 $0.2 * Excludes impact of restructuring and non-recurring items and amortization of goodwill. ** Midpoint of guidance as of February 9, 2006. Excludes equity compensation expense related to
Slide 5: Serving Large and Growing Markets
Markets Served Global Market: $50 Billion Long Term Growth Rate: 5 - 8% Bipharma 7 Safety 12 Clinical 10 Scientific Research 23 U.S. Clinical Lab ($10 billion) U.S. Lab Safety and Personal Protection ($12 billion) Global Scientific Research ($23 billion) Global Biopharma Production ($5 billion) No C
Slide 6: Customer Value Proposition
Customer Value Proposition Global operations Increasing complexity Cost pressures Customer Dynamics Fisher Value Proposition Broad product offering Global capabilities Suite of value-added services Cost reductions Accelerated product development Customer Benefits
Slide 7: Leverage Channel Position
Leverage Channel Position Other Suppliers Customers Proprietary Products Value-Added Services
Slide 8: Significant Free Cash Flow Generation
2001 2002 2003 2004 2005 2006F CAGR: 35% 8 * Free cash flow is defined as cash flow from operating activities less capital expenditures. See Supplementary Financial Information. Midpoint of 2006 guidance range of $525-$550 million as of February 9, 2006. Significant Free Cash Flow Generation *
Slide 9: Attractive Earnings per Share Growth
* Range of 2006 guidance as of February 9, 2006. Excludes equity compensation expense related to FAS 123r and results of Lab Workstations. Excludes restructuring and non-recurring items and amortization of goodwill. See Supplementary Financial Information. CAGR: 26% Attractive Earnings per Share Gro
Slide 10: Investment Highlights
Investment Highlights Leader in large and growing markets Proven track record Strong platform for growth Significant cash flow generation
Slide 11: The World Leader in Serving Science
The World Leader in Serving Science
Slide 12: Supplementary Financial Information
(in millions, except per share amounts) Supplementary Financial Information 12